FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March 2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Director/PDMR Shareholding
25 March 2021 15:00 GMT
Transactions by Persons Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announced that, on 23 and 24 March
2021, awards of the Company's ordinary shares of $0.25 each
(Ordinary Shares) vested to certain Persons Discharging Managerial
Responsibilities of the Company (PDMRs) under the AstraZeneca
Deferred Bonus Plan (AZDBP) and AstraZeneca Performance Share Plans
(AZPSP).
The AZDBP award was granted on 23 March 2018, following the
deferral of a portion of each PDMR's annual bonus paid in respect
of 2017 performance into Ordinary Shares, and vested on completion
of the three-year holding period.
The AZPSP award was granted on 24 March 2016 and was subject to a
three-year performance period. On the third anniversary of grant
the award was placed in a two-year holding period. The award vested
at the end of that holding period. Application of the performance
measures specified at the time of grant resulted in 79% of the
AZPSP award vesting and the remaining unvested part
lapsing.
Following the reinvestment of dividends accrued during the
performance and holding periods of the AZPSP award and during the
deferral period of the AZDBP award, and the withholding of shares
to satisfy certain tax obligations arising on vesting, the PDMRs'
beneficial interests in Ordinary Shares changed as detailed in the
table below:
PDMR
|
Ordinary Shares acquired under the AZDBP
|
Ordinary Shares acquired under the AZPSP
|
Pascal
Soriot
|
13,241
|
110,966
|
Marc
Dunoyer
|
4,214
|
27,355
|
For tax purposes, the fair market value of an Ordinary Share at
vest of the AZDBP award was 7344 pence, being the closing price on
the last trading day preceding the vesting. The fair market value
of an Ordinary Share at vest of the AZPSP award was 7215 pence,
being the closing price on the last trading day preceding the
vesting.
Further details are set out in the attached notifications, made in
accordance with the requirements of the EU and UK Market Abuse
Regulations.
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
a)
|
Name
|
Pascal
Soriot
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Chief
Executive Officer
|
b)
|
Initial notification /Amendment
|
Initial
notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
AstraZeneca
PLC
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
4i
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial instrument, type of
instrument
Identification
code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
b)
|
Nature of the transaction
|
Acquisition
of ordinary shares pursuant to a vesting under the AstraZeneca
Deferred Bonus Plan, for nil consideration.
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
0
|
13,241
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
e)
|
Date of the transaction
|
23
March 2021
|
f)
|
Place of the transaction
|
Outside
a trading venue
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
a)
|
Name
|
Marc
Dunoyer
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Chief
Financial Officer
|
b)
|
Initial notification /Amendment
|
Initial
notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
AstraZeneca
PLC
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
4i
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial instrument, type of
instrument
Identification
code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
b)
|
Nature of the transaction
|
Acquisition
of ordinary shares pursuant to a vesting under the AstraZeneca
Deferred Bonus Plan, for nil consideration.
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
0
|
4,214
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
e)
|
Date of the transaction
|
23
March 2021
|
f)
|
Place of the transaction
|
Outside
a trading venue
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
a)
|
Name
|
Pascal
Soriot
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Chief
Executive Officer
|
b)
|
Initial notification /Amendment
|
Initial
notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
AstraZeneca
PLC
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
4i
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial instrument, type of
instrument
Identification
code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
b)
|
Nature of the transaction
|
Acquisition
of ordinary shares pursuant to a vesting under the AstraZeneca
Performance Share Plan, for nil consideration.
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
0
|
110,966
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
e)
|
Date of the transaction
|
24
March 2021
|
f)
|
Place of the transaction
|
Outside
a trading venue
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
a)
|
Name
|
Marc
Dunoyer
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Chief
Financial Officer
|
b)
|
Initial notification /Amendment
|
Initial
notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
AstraZeneca
PLC
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
4i
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial instrument, type of
instrument
Identification
code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
b)
|
Nature of the transaction
|
Acquisition
of ordinary shares pursuant to a vesting under the AstraZeneca
Performance Share Plan, for nil consideration.
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
0
|
27,355
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
e)
|
Date of the transaction
|
24
March 2021
|
f)
|
Place of the transaction
|
Outside
a trading venue
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three therapy
areas - Oncology, Cardiovascular, Renal & Metabolism, and
Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
25 March
2021
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|